RE:RE:RE:FDA & DonnatalSorry to hear you sold VRX for CXR honestly. Let's face it, CXR's business plan was pretty much to be a copycat of VRX but in an even greedier way, by buying mostly non-branded drugs and/or stripping them off to get the generic approval. Believe what you want, but I think they're in worse shape than Valeant because, as bad as VRX was, at least they knew how to run the show. There's a reason it keeps getting called the ''baby Valeant'' and it's because the business is modeled on it. Even Thompson directly admitted it in 2015 by comparing his strategy to that of Pearson's only to distance himself later when it was clear that the comparison was no longer favorable. I don't care really if you think it's a great opportunity...if you're biased that way there's nothing that can be done but be sure to hedge and be cautious. You may think your margin of safety is good, and the numbers look OK, but the greatest quality in investing is knowing you can be wrong because you will be, often times. Admit that you don't always know, and be prepared to react beat a hasty retreat when you've made a mistake. Never invest without an exit plan. That being said, best of luck regardless of our diverging views.
Marky1 wrote: Great post CN....I mildly agree with you....hard getting clear answers out of them! The stock that I owned before was VRX and they were a lot more clear of where the company was heading..